About Golgin subfamily A member 6-like protein 22
Golgin subfamily A member 6-like protein 22 (GOLGA6L22) is a protein
from Homo sapiens identified by UniProt accession
H0YM25, 854 residues long.
MolForge cross-references it against 0 known binders and
0 disease associations.
Target properties
| Protein name | Golgin subfamily A member 6-like protein 22 |
| UniProt accession | H0YM25 |
| Gene | GOLGA6L22 |
| Organism | Homo sapiens |
| Length | 854 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-H0YM25-F1 | alphafold | PREDICTED | 71.58 | — |
Amino-acid sequence (854 residues)
MLMWPQPHLP THPHLPTHPH LPTHPHLPTH PHLPTHPHLP THPMMSKETR QSKLAEAKEQ LTDHHPQTNP SVGTAASDTK KKKINNGTSP ETTTSGGCHS PEDEQKASHQ HQEALRRELE AQVHTIRILT CQKTELQMAL YYSQHAVKQL EGEARDLISR LHDSWKFAGE LEQALSAVTT QKKKADRYIE ELTKERDALS LELYRNTITD EELKEKNAKL QEKLQLVESE KSEIQLNVKE LKRKLERAKL LLPQQQLQAE ADHLGKELQS VSAKLQAQVE ENELWNRLNQ QQEEKMWRQE EKIQEWEEKI QEQEEKIREQ EEKIREQEEK MRRQEEMMWE KEEKMRRQEE MMWEKEEKIR ELEEKMHEQE KIREQEEKRQ EEEKIREQEK RQEQEAKMWR QEEKIREQEE KIREQEKKMW RQEEKIHEQE KIREEEKRQE QEEMWRQEEK IREQEEIWRQ KEKMHEQEEK IRKQEEKVWR QEEKMHDQEE KIREQEEKVW RQEEKIREQE KKREQEEKMW RQEEKIREQE EKIREQEEMW REEEKMHEQE KIWEEEKRQE QEDKMWRQEE KIREQEEKVW RQEEKIREQE EKRQEQEEKM WKQEEKIREQ EEKIREQEEK IREQEEKIRE QEEMMQEQEE KMGEQEEKMQ EQEKMRRQEE KIREQEEKIR EQKEKIREQE EKIWEQEEKI REQEEMMQEQ EEKMGEQEEK IWEQEEKMQE QEEKMRRQEE KIREQEKKIR EQEEKIREQE EMMQEQEEKM GEQEEKMQEQ EEKMRRQEEK IREQEKKIRE QEEKIREQEE MMQEQEEKMW EQEEKMCEQE EKMQEQEEKM RRQEEKMWEQ EVRLRQQEEK MQEH
Explore Golgin subfamily A member 6-like protein 22 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets